Well-established factors predicting virological response to PEGIFN/RBV-treatment in HIV/HCV coinfection include HCV GT, HCV-RNA, IL28B [26], liver fibrosis, insulin resistance, low-density lipoprotein (LDL)-cholesterol-levels[50], low CD4+ counts and nadirs [51] and y-glutamyltransferase (GGT) levels [50]. Here, CD4 is linked to Hepatic fibrosis.